Clinical application progress of novel targeted drug gilteritinib in treatment of acute myeloid leukemia with FLT3 mutation

VernacularTitle:新型靶向药吉瑞替尼在伴FLT3突变急性髓系白血病治疗的临床应用进展
Author: Rongli ZHANG ¹ ; Erlie JIANG
Author Information

1. 中国医学科学院血液病医院（中国医学科学院血液学研究所）　实验血液学国家重点实验室　国家血液系统疾病临床医学研究中心　细胞生态海河实验室，天津　300020
Keywords: Leukemia, myeloid, acute; Gene mutation; Fms-like tyrosine kinase 3; Gilteritinib
From: Journal of Leukemia & Lymphoma 2023;32(6):377-381
CountryChina
Language:Chinese
Abstract: Acute myeloid leukemia (AML) patients with FLT3 mutation have a high risk of recurrence and poor prognosis. The first generation of drugs targeting FLT3 represented by sorafenib show poor selectivity and efficacy in the treatment of AML, whereas the new second-generation FLT3 inhibitors represented by gilteritinib have a stronger inhibitory effect on FLT3, higher specificity and lower off-target toxicity, which greatly improves the outcomes of AML patients with FLT3 mutation. This article reviews the action mechanism and the clinical progress of gilteritinib.